蓝光联合益生菌口服治疗早产儿黄疸临床观察

发布时间：2018-11-03 19:24

【摘要】：目的观察蓝光联合亿活(布拉氏酵母菌)或贝飞达(双歧杆菌三联活菌肠溶胶囊)治疗早产儿黄疸的临床效果。方法选取入住中南大学湘雅医学院附属海口医院新生儿重症监护室(NICU)出现黄疸需蓝光治疗的早产儿(28周胎龄37周)113例,将其随机分为A、B、C三组,分别为41、37、35例,其中A组予常规蓝光治疗;B组蓝光治疗同时给予口服亿活0.125 g/次,2次/d;C组蓝光治疗同时给予口服贝飞达0.105 g/次,2次/d;观察入院后开始蓝光或联合益生菌治疗至住院第8天,比较三组总光疗时间、蓝光治疗前与住院第8天经皮测胆红素(TCB)下降的幅度、蓝光治疗相关不良反应发生率。结果 A、B、C组总光疗时间分别为(3.829±2.234)、(2.621±1.972)、(2.894±1.594)d,三组间比较,P均0.05。A、B、C组光疗前TCB水平分别为(155.319±50.171)、(171.171±44.511)、(157.713±46.067)μmol/L,住院第8天TCB水平分别为(149.557±41.399)、(146.410±33.670)、(141.349±37.945)μmol/L,三组间光疗前TCB、住院第8天TCB比较均无统计学差异(P均0.05)。A、B、C组蓝光治疗相关不良反应(腹泻、皮疹及发热等)发生率分别为34.1%、37.8%、37.1%,三组不良反应发生率比较差异无统计学意义(P0.05)。结论口服益生菌联合蓝光治疗早产儿黄疸效果较好,且较为安全;其机制可能与亿活能调节肠道运动及降低肠道内β-葡萄糖醛酸苷酶活性减少胆红素肠肝循环有关。
[Abstract]:Objective to observe the clinical effect of blue light combined with yeasts (Saccharomyces brasiliensis) or befeida (Bifidobacterium triplex enteric capsule) in the treatment of premature jaundice. Methods 113 premature infants with jaundice (28 weeks gestational age 37 weeks) who were admitted to the neonatal intensive care unit of Haikou Hospital affiliated to Xiangya Medical College of Central South University were randomly divided into three groups: 41 cases (37 cases). Group A was treated with conventional blue light. Group B was treated with blue light at the same time, and group C was treated with buflon 0.105 g / time, twice a day. The total phototherapy time before and after admission, the extent of the decrease of bilirubin (TCB) before and after blue light therapy and the incidence of adverse reactions associated with blue light therapy were observed. Results the total time of phototherapy was (3.829 卤2.234), (2.621 卤1.972), (2.894 卤1.594) d in group A (P 0.05). The level of TCB in group C was (155.319 卤50.171) before phototherapy. The TCB level of (171.171 卤44.511), (卤46.067) 渭 mol/L, on the 8th day of hospitalization was (149.557 卤41.399), (146.410 卤33.670), (141.349 卤37.945) 渭 mol/L, before phototherapy. The incidence of adverse reactions (diarrhea, rash, fever, etc.) associated with blue light therapy in group A were 34.1% and 37.8%, respectively. There was no significant difference in the incidence of adverse reactions among the three groups (P0.05). Conclusion Oral probiotics combined with blue light is effective and safe in the treatment of premature jaundice, and its mechanism may be related to the regulation of intestinal motility and the decrease of 尾 -glucuronidase activity in intestinal tract and the reduction of intestinal hepatic circulation of bilirubin.
【作者单位】：中南大学湘雅医学院附属海口医院;
【基金】：海口市重点科技计划项目(2014-069)
【分类号】：R722.6

【参考文献】